Inogen, Inc. (INGN) is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter 2024 performance and a strong product portfolio, seems justified. However, issues like stiff competition and forex volatility are major downsides. The Zacks Rank #2 (Buy) company's shares have risen 106.4% year to date compared with 9.2% growth of the industry. The S&P 500 has increased 17.7% during the same time frame. The ...

Inogen (INGN) witnessed strong momentum in the year-to-date period. Shares of the company have surged 127.1% compared with 9.1% growth of the industry. The S&P 500 composite has risen 17.4% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in Goleta, CA, Inogen develops, manufactures and markets portable oxygen concentrators (POCs), used by patients who s ...

For the quarter ended June 2024, Inogen (INGN) reported revenue of $88.77 million, up 6.1% over the same period last year. EPS came in at -$0.24, compared to -$0.42 in the year-ago quarter. The reported revenue represents a surprise of +7.80% over the Zacks Consensus Estimate of $82.34 million. With the consensus EPS estimate being -$0.54, the EPS surprise was +55.56%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file ...

Inogen, Inc. (INGN) incurred an adjusted loss per share of 7 cents for the second quarter of 2024, narrower than the adjusted loss per share of 25 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 54 cents per share. GAAP loss per share for the quarter was 24 cents, better than the year-earlier loss of 42 cents per share. Revenues in Detail Inogen registered revenues of $88.8 million for the second quarter, up 6.1% year over year. The figure beat the Zacks Consensus Estimate ...

Inogen, Inc. (NASDAQ:INGN) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Ryan Peterson - IR Kevin Smith - President and CEO Mike Bourque - CFO Conference Call Participants Lilia-Celine Lozada - JPMorgan James Beer - William Blair Colin Clark - Stifel Michael Matson - Needham & Company Operator Welcome to Inogen's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, August 6, 2024. I would now like to t ...

Inogen (INGN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 55.56%. A quarter ago, it was expected that this produces oxygen concentrators for patients suffering from chronic respiratory conditions would post a loss of $0.76 per share when it actually produced a loss of $0.62, delivering a ...

Exhibit 99.1 Inogen Announces Second Quarter 2024 Financial Results GOLETA, Calif., – August 6, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2024. "I am proud of the performance of our team in the first half of 2024. We have made meaningful progress on our strategic initiatives, driving top-line growth and advancing the profile of the business toward ...

Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10. The fundamentals behind these companies may diversify portfolios with high potential. These companies' financial performance and strategic initiatives explain why these small-cap stocks are poised for high gains. Source: Poetra.RH / Shutterstock.com The first one has consistently demonstrated impr ...

The renowned provider of POCs has a market capitalization of $212.4 million. The company projects 50.2% growth for 2024 and expects to witness continued improvements in its business. Inogen's P/S ratio of 0.7X compares favorably with the industry's 3.1X. Downsides The Zacks Consensus Estimate for second-quarter 2024 revenues is pegged at $82.3 million, suggesting a 1.6% decline from the year-ago reported number. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22.9%. DX ...